Normal view

Received — 17 March 2026 ⏭

Nature Medicine
First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial Kohei Shitara · Hirokazu Shoji · Nicola Fazio · Sara Lonardi · Keun-Wook Lee · Li-Yuan Bai · Kensei Yamaguchi · Jean-Philippe Metges · Gianluca Masi · Denis Smith · Tae-Yong Kim · Maria Matsangou · Archita Shrivastava · Miaomai Zhou · Jason Hill · Abraham Guerrero · Xuewei Wang · Aziz Zaanan · Samuel J. Klempner
Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.
16 March 2026 at 08:00

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

By: Kohei Shitara · Hirokazu Shoji · Nicola Fazio · Sara Lonardi · Keun-Wook Lee · Li-Yuan Bai · Kensei Yamaguchi · Jean-Philippe Metges · Gianluca Masi · Denis Smith · Tae-Yong Kim · Maria Matsangou · Archita Shrivastava · Miaomai Zhou · Jason Hill · Abraham Guerrero · Xuewei Wang · Aziz Zaanan · Samuel J. Klempner

16 March 2026 at 08:00

Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9

In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.